Drug intelligence / Profile preview

I-131 iodocholesterol

Development stage
Unknown
Lead developer
University of Texas MD Anderson Cancer Center
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

I-131 iodocholesterol (131I-19-iodocholesterol) is a radiopharmaceutical diagnostic agent developed for the visualization of the adrenal cortex. It consists of cholesterol labeled with the radioisotope iodine-131. As cholesterol is a primary precursor for steroid hormone synthesis, the radiotracer is taken up by the adrenal glands via lipoprotein receptors, primarily the low-density lipoprotein (LDL) receptor. Once accumulated, the gamma emissions from I-131 allow for scintigraphic imaging (gamma imaging) to evaluate adrenal function and detect abnormalities such as Cushing's syndrome, primary hyperaldosteronism, and adrenal neoplasms (adenomas and carcinomas). While it was a pioneering agent in adrenal imaging, it was largely superseded by the second-generation agent NP-59 (131I-6β-iodomethyl-19-norcholesterol) due to the latter's higher adrenal avidity and lower background interference.

Other names
Iodine I-131 Iodocholesterol19-iodocholesterol131I-cholesterol
02

Targets

LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on I-131 iodocholesterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on I-131 iodocholesterol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call